Since the approval of Enbrel®, CD4 – Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion protein therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion protein based drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion